STOCK MARKET BSE NSE

Aurobindo Pharma shares plunge over 6 per cent after USFDA warning letter for subsidiary

Aurobindo Pharma said it believes the existing business from this facility will not be impacted.

Published: 22nd October 2020 12:17 PM  |   Last Updated: 22nd October 2020 12:17 PM   |  A+A-

Stocks, BSE, Sensex, NSE

For representational purposes.

By PTI

NEW DELHI: Shares of Aurobindo Pharma on Thursday tanked over 6 per cent after the company's step-down subsidiary received a warning letter from the US health regulator for its unit in New Jersey, US.

The stock declined 6.37 per cent to Rs 754 on the BSE. On the NSE, it fell 6.53 per cent to Rs 753.50. AuroLife Pharma, a wholly-owned step-down subsidiary of the company, has received a warning letter from the United States Food and Drug Administration (USFDA) for its oral solid manufacturing facility situated at Dayton, New Jersey, Aurobindo Pharma said in a BSE filing.

This follows the earlier letter dated June 4, 2020, issuing an OAI (Official Action Indicated) status for this facility.

Aurobindo Pharma said it believes the existing business from this facility will not be impacted. "The company will be engaging with the regulator and is fully committed in resolving this issue at the earliest," it added. The drug firm, however, did not provide any details of the contents of the warning letter.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp